8-K: Avalon GloboCare Secures $200,000 Through Convertible Notes with High Interest and Potential Dilution

Avalon GloboCare Corp. has entered into agreements for two convertible promissory notes totaling $200,000, bearing a significant one-time interest charge and offering conversion into common stock at a fixed price, subject to ownership and exchange limitations.

Summary

• Avalon GloboCare Corp. issued two Convertible Promissory Notes, each with a principal amount of $100,000, to two accredited investors.
• The notes carry a one-time interest charge of $30,000 per note, totaling $60,000 in interest for the $200,000 principal.
• The notes mature nine months from the issue date, which is April 3, 2026.
• Investors can convert outstanding principal and accrued interest into common stock at a fixed conversion price of $1.00 per share, starting six months after the issue date (January 3, 2026).
• Conversion is subject to a beneficial ownership limitation, restricting investors from owning more than 4.99% of the company's outstanding common stock post-conversion.
• An Exchange Cap limits the total shares issuable under each note to 19.99% of outstanding common stock, requiring shareholder approval for issuance beyond this cap.
• The company has the right to prepay the notes at any time without penalty.
• The notes are unsecured and rank junior to all secured indebtedness.
• As a commitment fee, 5,000 shares of restricted common stock were issued to each investor, totaling 10,000 shares.

Sentiment

Score: 4

Explanation: The company successfully raised $200,000, which is positive for liquidity. However, the high effective interest rate of 30% for nine months and the immediate issuance of commitment shares indicate a costly financing arrangement. The potential for significant future dilution and the unsecured, junior ranking of the debt also present notable drawbacks.

Positives

• Secured $200,000 in financing, providing additional capital.
• Company retains the right to prepay the notes at any time without penalty, offering financial flexibility.
• Fixed conversion price of $1.00 per share provides clarity for potential future conversions.

Negatives

• High one-time interest charge of $30,000 per $100,000 note, effectively a 30% interest rate for nine months, which is substantial.
• Issuance of 10,000 shares of restricted common stock as a commitment fee further dilutes existing shareholders.
• The notes are unsecured and rank junior to all secured indebtedness, increasing risk for these noteholders in case of default or liquidation.
• Potential for significant future dilution if notes are converted into common stock, especially if shareholder approval is obtained to exceed the 19.99% exchange cap.

Risks

• Dilution Risk: Conversion of the notes into common stock and the issuance of commitment shares will dilute the ownership percentage of existing shareholders.
• Shareholder Approval Risk: Issuance of shares exceeding 19.99% of outstanding common stock requires shareholder approval, which may not be obtained, potentially limiting the company's ability to fully satisfy conversion requests with equity.
• Subordination Risk: The notes are unsecured and junior to all secured indebtedness, meaning noteholders would have lower priority in receiving payments in the event of bankruptcy or liquidation.
• Default Risk: Events of default, including failure to pay, bankruptcy, or breach of covenants, could lead to immediate acceleration of the notes' due date.
• Market Price Volatility: The fixed conversion price of $1.00 per share means that if the stock price falls significantly below this, conversion becomes less attractive for investors, potentially leading to cash repayment demands at maturity.

Future Outlook

The company's ability to satisfy future conversion requests beyond a 19.99% exchange cap is contingent upon obtaining shareholder approval in accordance with Nasdaq Listing Rule 5635(d).

Management Comments

• The Company covenants that at all times until the Note is satisfied in full, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of a number of Conversion Shares issuable upon the full conversion of this Note.
• The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate or Articles of Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Note, and will at all times in good faith carry out all the provisions of this Note and take all action as may be required to protect the rights of the Holder.

Industry Context

This financing event is a common method for smaller or developing companies, particularly in the biotech or healthcare sectors (implied by 'Globocare'), to raise capital without immediate equity dilution from a public offering, often at terms reflecting the company's risk profile and access to traditional debt markets.

Stakeholder Impact

• Shareholders: Potential for dilution from the conversion of notes and the issuance of commitment shares. The need for shareholder approval for conversions exceeding 19.99% gives existing shareholders a say in significant dilution events.
• Creditors: The new notes are unsecured and rank junior to all secured indebtedness, meaning existing secured creditors maintain their priority.

Next Steps

• Potential conversion of notes into common stock by investors starting January 3, 2026.
• Repayment of notes by April 3, 2026, if not converted.
• Potential need for shareholder approval to issue shares beyond the 19.99% exchange cap.

Key Dates

Recommendation

Keywords

Avalon GloboCare Corp., ALBT, Convertible Promissory Notes, Debt Financing, Equity Dilution, SEC Filing, Form 8-K, Capital Raise, Unsecured Debt, Nasdaq Listing Rule 5635(d), Accredited Investors, Commitment Shares